AZ looks to grow reach in lupus with phase 3 win for self-administered Saphnelo
The full results from AstraZeneca’s phase 3 Tulip-SC trial build on the interim results that earned the drug a European approval last month. Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the self-administered drug formulation in lupus patients with a positive phase 3 […]
Novo’s oral semaglutide edges out CagriSema, Lilly’s orforglipron as PCPs’ most-anticipated obesity med
Oral semaglutide, which Novo has taken to calling “Wegovy in a pill,” is expected to receive an FDA decision before the end of the year. As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers. Spherix Global Insights surveyed […]
A Glimpse Inside the CLE Pipeline: What’s Coming Down the Pike?
Dermatologists rely heavily on topical therapies for cutaneous lupus erythematosus (CLE), but are increasingly interested in systemic agents with user-friendly formulations and dermatology-relevant experience such as deucravacitinib (Sotyktu BMS), an oral TYK2 inhibitor currently approved for psoriasis. Familiarity with its mechanism and a favorable safety profile have positioned deucravacitinib as a top contender for future […]
